27th University of Chicago Comprehensive Cancer Center Developmental Therapeutics Symposium
- Analyze Cutting-Edge Data: Delve into curated data from completed studies to gain unique insights.
- Explore Novel Investigational Agents: Discover the latest advancements in ongoing clinical trials, equipping yourself with valuable knowledge on groundbreaking therapies.
- Uncover Research Rationale and Results: Gain a comprehensive understanding of the motivations and findings behind studies involving innovative agents for advanced cancer treatment.
This symposium is your bridge to mastering precision medicine in oncology, ultimately transforming the lives of cancer patients for the better. Join us in shaping the future of cancer care!
Target Audience
Learning Objectives
After this activity, participants will be able to:
- Recall new approaches to pre- and post-FDA approval for dosing and scheduling of anti-cancer agents;
- Recognize the therapeutic ratio of novel agents and approaches to define dose reductions that maintain efficacy;
- State the clinical effects of novel immunotherapeutic agents, including novel checkpoint inhibitors, bispecific antibodies, and novel cellular therapies;
- Identify how to assess patient suitability for participation in ongoing and upcoming cancer clinical trials and projects;
- Cite the relevant pharmacologic and biologic effects of novel anti-cancer agents through the use of blood and tissue samples as well as standard and novel imaging approaches, including novel PET tracer imaging and circulating tumor DNA assays;
- Discuss the current science related to radioligand therapy and available agents;
- Describe advances in the use of systemic therapies for cancer, including those targeting specific molecular alterations such as DNA repair mutations, specific chromosomal translocations, and tyrosine kinase mutations;
- Assess the status of and developmental pathway for antibody-drug conjugates in solid and hematologic tumors.
- 5.25 ABIM Medical Knowledge
- 5.25 AMA PRA Category 1 Credit™
- 5.25 Nursing Contact Hours
- 5.25 Participation
Session Time | Session Name | Moderator(s) | Speakers |
---|---|---|---|
8:15 - 8:45 AM | Registration / Breakfast / Exhibits Open | ||
8:45 - 10:05 AM | Welcome The Current Landscape of Novel Therapeutics in Breast Cancer Advances in NSCLC New Frontiers: Novel Therapeutic Approaches in Head & Neck Cancer | Walter Stadler, MD | Nan Chen, MD Rajat Thawani, MD Ari Rosenberg, MD |
10:05 - 10:25 AM | Break / Visit Exhibits | ||
10:25 AM - 12:05 PM | BCMA & Beyond: The Next Generation of Immunotherapies in Multiple Myeloma Emerging Targets & Strategies in Hepatobiliary Cancers Optimizing Cellular Therapy in Lymphoma The Evolving Treatment Paradigm for Acute Leukemia & Myeloid Neoplasms | Toyosi Odenike, MD | Benjamin Derman, MD Joseph Franses, MD, PhD Peter Riedell, MD Anand Patel, MD |
12:05 - 1:05 PM | Lunch & Lunchtime Breakouts | ||
12:20 - 1:05 PM | *Concurrent Lunchtime Breakouts: | ||
1. Internal Research Staff & Nurses: Regulatory and Pragmatic Issues for Running Cancer & Clinical Trials | Lauren Wall | Livia Szeto Sara Moellering Lauren Wall | |
2. Physicians: Dose Optimization in Cancer Drug Development | Walter Stadler, MD | Mark Ratain, MD | |
1:05 - 1:20 PM | Break & Visit Exhibits | ||
1:20 - 2:35 PM | Advancing Solid Tumor Cell Therapy Novel Therapies in Gynecologic Malignancies Novel Precision Therapeutics in GU Malignancies: Theranostics & Antibody Conjugates | Toyosi Odenike, MD | Dan Olson, MD John Moroney, MD Russ Szmulewitz, MD |
2:35 - 2:40 PM | Closing Remarks | Toyosi Odenike, MD | Walter Stadler, MD Toyosi Odenike, MD |
2:40 PM | Adjourn | ||
2:40 - 3:40 PM | Trainees Post-Conference Reception: Developing a Career in Clinical Research | Walter Stadler, MD Toyosi Odenike, MD |
*The agenda is subject to change.
DAVID RUBENSTEIN FORUM
WANT TO KNOW MORE?
Visit the David Rubenstrein Forum's website! For more information about the program, contact Meeting Achievements via e-mail.
SPECIAL PARTICIPANT RATES ARE AVAILABLE!
Featuring 167 rooms including nine brand signature Study units and a complement of premium Suites. Rooms are equipped with all the amenities the modern traveler needs—whether he or she is a scholarly guest seeking the perfect leather reading chair, a visiting executive in need of an expansive work desk, or a prospective student looking for a view of the campus through floor-to-ceiling windows. All guestrooms feature comfortable feather-topped beds, Frette linens and towels, a soft leather chair and ottoman from Mitchell Gold + Bob Williams, lighting from Spain-based Marset, and modern bathrooms with C.O. Bigelow toiletries. Guests enjoy essential complimentary amenities including wireless high-speed Internet, bottled water, newspapers, and morning coffee available through our Living Room.
The Study is located at 1227 E 60th St, right next door to the Rubenstein Forum. Learn more at their website.
Rates $259/night (Rate does not include applicable state and local taxes.)
Reservations When calling or emailing, reference the group name: Developmental Therapeutics Symposium
• Email: [email protected]
• Individual guests must make their reservations no later than April 9, 2024, at 5:00 PM CST.
Check-in/Check-Out Check-in time is 3:00 PM. Checkout time is noon.
VISITING CHICAGO
UNIVERSITY OF CHICAGO COURSE DIRECTORS
Fred C. Buffett Professor of Medicine and Surgery
Dean for Clinical Research
Senior Advisor to Comprehensive Cancer Center Director
Disclosure Declarations
As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone in a position to control the content of an education activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships prior to the start of the activity.
Additionally, The University of Chicago Pritzker School of Medicine requires Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration at first mention and where appropriate in the content.
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Other participants will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.
EXHIBIT OPPORTUNITIES ARE AVAILABLE!
REGISTRATION
After logging in/creating an account, select your registration type below and click "Register Now!" Simply follow the prompts to complete your registration.
Profession Type | Fee |
---|---|
Physician | $50 |
Healthcare Professional | $25 |
Trainee | $25 |
Industry | $350 |
CANCELLATION POLICY: If you cancel your participation in this conference, your registration fee less a 50% administrative fee will be refunded when written notification is received by April 10, 2024. No refunds will be made after April 10, 2024. |
CLAIMING CREDIT
At the end of the activity, the credit-claiming process will unlock. Return to this page and click on "Complete Activity" to proceed.
Please Note: Requests to claim MOC Part II credit must be made within one month to report to ABIM. Requests to claim AMA PRA Category 1 Credit™ after three months will be subject to additional fees.